EE04399B1 - Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis - Google Patents
Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravisInfo
- Publication number
- EE04399B1 EE04399B1 EEP200000031A EEP200000031A EE04399B1 EE 04399 B1 EE04399 B1 EE 04399B1 EE P200000031 A EEP200000031 A EE P200000031A EE P200000031 A EEP200000031 A EE P200000031A EE 04399 B1 EE04399 B1 EE 04399B1
- Authority
- EE
- Estonia
- Prior art keywords
- therapy
- preparation
- pharmaceutical compositions
- compositions containing
- heterocyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9702746A SE9702746D0 (sv) | 1997-07-18 | 1997-07-18 | New compounds |
SE9800977A SE9800977D0 (sv) | 1998-03-24 | 1998-03-24 | New compounds |
PCT/SE1998/001364 WO1999003859A1 (en) | 1997-07-18 | 1998-07-10 | Novel spiroazabicyclic heterocyclic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200000031A EE200000031A (et) | 2000-10-16 |
EE04399B1 true EE04399B1 (et) | 2004-12-15 |
Family
ID=26663041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200000031A EE04399B1 (et) | 1997-07-18 | 1998-07-10 | Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis |
Country Status (31)
Country | Link |
---|---|
US (6) | US6110914A (is) |
EP (2) | EP0996622B1 (is) |
JP (1) | JP2001510194A (is) |
KR (1) | KR100560036B1 (is) |
CN (1) | CN1117755C (is) |
AR (2) | AR013184A1 (is) |
AT (2) | ATE225792T1 (is) |
AU (1) | AU739022B2 (is) |
BR (1) | BR9810924A (is) |
CA (1) | CA2296031C (is) |
DE (2) | DE69827977T2 (is) |
DK (1) | DK0996622T3 (is) |
EE (1) | EE04399B1 (is) |
ES (2) | ES2185185T3 (is) |
HK (3) | HK1025322A1 (is) |
HU (1) | HUP0003844A3 (is) |
ID (1) | ID25548A (is) |
IL (2) | IL134086A0 (is) |
IS (2) | IS2027B (is) |
MY (1) | MY116761A (is) |
NO (1) | NO325324B1 (is) |
NZ (1) | NZ502298A (is) |
PL (1) | PL193065B1 (is) |
PT (1) | PT996622E (is) |
RU (1) | RU2202553C2 (is) |
SA (1) | SA98190668B1 (is) |
SI (1) | SI0996622T1 (is) |
SK (1) | SK283484B6 (is) |
TR (1) | TR200000129T2 (is) |
TW (1) | TW515799B (is) |
WO (1) | WO1999003859A1 (is) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ500643A (en) | 1997-05-30 | 2001-12-21 | Neurosearch As | Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators |
US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
FR2790474B1 (fr) * | 1999-03-05 | 2001-04-06 | Synthelabo | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
TWI298068B (en) * | 2000-06-21 | 2008-06-21 | Dainippon Sumitomo Pharma Co | Pharmaceutical composition for schizophrenia |
ATE353332T1 (de) * | 2001-06-01 | 2007-02-15 | Astrazeneca Ab | Neuer, für die therapie geeigneter ligand für nikotinische acetylcholinrezeptoren |
US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
EP1453828A2 (en) * | 2001-10-16 | 2004-09-08 | AstraZeneca AB | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
EP1463481A4 (en) * | 2001-12-14 | 2008-06-25 | Targacept Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
NZ535978A (en) * | 2002-04-18 | 2007-10-26 | Astrazeneca Ab | Novel spiroazabicyclic heterocyclic amines useful as nicotinic acetylcholine receptor agonists |
CA2482313A1 (en) * | 2002-04-18 | 2003-10-23 | Astrazeneca Ab | Heterocyclic compounds |
CN1325500C (zh) * | 2002-04-18 | 2007-07-11 | 阿斯特拉曾尼卡有限公司 | 呋喃基化合物 |
AU2003257145B2 (en) | 2002-08-02 | 2008-11-13 | Merck Sharp & Dohme Corp. | Substituted furo (2,3-b) pyridine derivatives |
SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
EP2062595A1 (en) * | 2002-12-06 | 2009-05-27 | The Feinstein Institute for Medical Research | Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists |
WO2004063201A1 (ja) * | 2003-01-08 | 2004-07-29 | Mitsubishi Pharma Corporation | 統合失調症治療剤 |
WO2005000250A2 (en) * | 2003-06-24 | 2005-01-06 | Johns Hopkins University | Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor |
WO2005030778A1 (en) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Ligands |
US7402592B2 (en) | 2003-10-15 | 2008-07-22 | Targacept, Inc. | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders |
CA2543436A1 (en) * | 2003-10-21 | 2005-05-12 | Astrazeneca Ab | Spirofuropyridine aryl derivatives |
AU2005225458B2 (en) | 2004-03-25 | 2008-12-04 | The Feinstein Institutes For Medical Research | Neural tourniquet |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
JP2008525102A (ja) | 2004-12-27 | 2008-07-17 | ノース ショア−ロング アイランド ジューウィッシュ リサーチ インスティテュート | 電気的な迷走神経刺激による炎症性障害の処置 |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
WO2007024814A1 (en) | 2005-08-22 | 2007-03-01 | Targacept, Inc. | HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
TW200813067A (en) * | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
US20080242688A1 (en) * | 2007-03-19 | 2008-10-02 | Astrazeneca Ab | Method 741 |
CA2682323A1 (en) | 2007-04-02 | 2008-10-09 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
MX2010003375A (es) | 2007-10-01 | 2010-05-17 | Comentis Inc | Derivados de 1h-indol-3-carboxilato de quinuclidin-4-ilmetilo como ligandos del receptor de acetilcolina alfa 7 nicotinico para el tratamiento de enfermedad de alzheimer. |
CN101977628A (zh) | 2008-02-13 | 2011-02-16 | 塔加西普特公司 | α7烟碱激动剂和抗精神病药的组合 |
US9211409B2 (en) | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
TWI488854B (zh) | 2008-06-20 | 2015-06-21 | Astrazeneca Ab | 二苯并噻氮呯衍生物及其用途 |
ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
CN102781963B (zh) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | 功能修饰性NAv1.7抗体 |
US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
WO2011079309A2 (en) | 2009-12-23 | 2011-06-30 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
WO2011116282A2 (en) | 2010-03-19 | 2011-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nicotinic acetylcholine receptor agonists |
ES2649539T3 (es) | 2010-05-17 | 2018-01-12 | Forum Pharmaceuticals Inc. | Formulaciones farmacéuticas que comprenden formas cristalinas de clorhidrato de (R)-7-cloro-N-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado |
EP2707094B1 (en) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
RU2455306C1 (ru) * | 2011-05-19 | 2012-07-10 | Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 3',4',5,6-ТЕТРАГИДРО-1Н-СПИРО[ПИРИДИН-4,5'-ТИЕНО[2,3-d]ПИРИМИДИНОВ] |
US20140128606A1 (en) | 2011-06-30 | 2014-05-08 | Toray Industries, Inc. | Antipruritic agent |
GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
US9593106B2 (en) | 2013-02-07 | 2017-03-14 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
US8893339B2 (en) | 2013-03-14 | 2014-11-25 | Select Comfort Corporation | System and method for adjusting settings of a bed with a remote control |
EA029430B1 (ru) | 2013-06-21 | 2018-03-30 | Такеда Фармасьютикл Компани Лимитед | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина |
GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AR101131A1 (es) | 2014-07-11 | 2016-11-23 | Comentis Inc | QUINUCLIDINAS PARA LA MODULACIÓN DE ACTIVIDAD DE a7 |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 薬剤送達方法及びシステム |
WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
WO2017127756A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Control of vagal stimulation |
EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
EP3856180A1 (en) * | 2018-09-24 | 2021-08-04 | Astrazeneca AB | Azd0328 dosage regime for treating cognitive impairment |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
JP2023526080A (ja) | 2020-05-21 | 2023-06-20 | ザ・フェインステイン・インスティチュート・フォー・メディカル・リサーチ | 迷走神経刺激のためのシステムおよび方法 |
CN115340736B (zh) * | 2022-05-20 | 2023-09-29 | 扬州实嘉电缆材料有限公司 | 一种氮磷阻燃剂改性聚氯乙烯防火电缆料 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3681363A (en) * | 1970-08-20 | 1972-08-01 | Univ Temple | Spiro(imidazolidine-4,3{40 -quinuclidine)-2,5-diones |
CA2196995C (en) * | 1994-08-24 | 2008-05-13 | Michael Balestra | Spiro-azabicyclic compounds useful in therapy |
US5468875A (en) * | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
ATE200084T1 (de) * | 1995-07-28 | 2001-04-15 | Abbott Lab | Furo-, thieno- und pyrrolopyridine und verwandte pyrinidin-, pyridazin- und triazinverbindungen verwendbar zur kontrolle von chemische synaptische übertragung |
AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
-
1998
- 1998-07-06 AR ARP980103280A patent/AR013184A1/es unknown
- 1998-07-10 NZ NZ502298A patent/NZ502298A/en unknown
- 1998-07-10 DE DE69827977T patent/DE69827977T2/de not_active Expired - Fee Related
- 1998-07-10 AT AT98934078T patent/ATE225792T1/de not_active IP Right Cessation
- 1998-07-10 CA CA002296031A patent/CA2296031C/en not_active Expired - Fee Related
- 1998-07-10 PL PL338259A patent/PL193065B1/pl not_active IP Right Cessation
- 1998-07-10 CN CN98809055A patent/CN1117755C/zh not_active Expired - Fee Related
- 1998-07-10 US US09/171,983 patent/US6110914A/en not_active Expired - Lifetime
- 1998-07-10 DE DE69808631T patent/DE69808631T2/de not_active Expired - Fee Related
- 1998-07-10 RU RU2000103958/04A patent/RU2202553C2/ru not_active IP Right Cessation
- 1998-07-10 EP EP98934078A patent/EP0996622B1/en not_active Expired - Lifetime
- 1998-07-10 EP EP02005982A patent/EP1213291B1/en not_active Expired - Lifetime
- 1998-07-10 KR KR1020007000526A patent/KR100560036B1/ko not_active IP Right Cessation
- 1998-07-10 AT AT02005982T patent/ATE283859T1/de not_active IP Right Cessation
- 1998-07-10 PT PT98934078T patent/PT996622E/pt unknown
- 1998-07-10 BR BR9810924-3A patent/BR9810924A/pt not_active Application Discontinuation
- 1998-07-10 ES ES98934078T patent/ES2185185T3/es not_active Expired - Lifetime
- 1998-07-10 EE EEP200000031A patent/EE04399B1/xx not_active IP Right Cessation
- 1998-07-10 DK DK98934078T patent/DK0996622T3/da active
- 1998-07-10 TR TR2000/00129T patent/TR200000129T2/xx unknown
- 1998-07-10 IL IL13408698A patent/IL134086A0/xx active IP Right Grant
- 1998-07-10 SI SI9830292T patent/SI0996622T1/xx unknown
- 1998-07-10 JP JP2000503083A patent/JP2001510194A/ja active Pending
- 1998-07-10 ID IDW20000024A patent/ID25548A/id unknown
- 1998-07-10 SK SK1835-99A patent/SK283484B6/sk not_active IP Right Cessation
- 1998-07-10 HU HU0003844A patent/HUP0003844A3/hu unknown
- 1998-07-10 ES ES02005982T patent/ES2231599T3/es not_active Expired - Lifetime
- 1998-07-10 WO PCT/SE1998/001364 patent/WO1999003859A1/en active IP Right Grant
- 1998-07-10 AU AU83679/98A patent/AU739022B2/en not_active Ceased
- 1998-07-16 MY MYPI98003255A patent/MY116761A/en unknown
- 1998-07-17 TW TW087111679A patent/TW515799B/zh not_active IP Right Cessation
- 1998-10-26 SA SA98190668A patent/SA98190668B1/ar unknown
-
2000
- 2000-01-13 IS IS5338A patent/IS2027B/is unknown
- 2000-01-17 IL IL134086A patent/IL134086A/en not_active IP Right Cessation
- 2000-01-17 NO NO20000226A patent/NO325324B1/no not_active IP Right Cessation
- 2000-06-16 US US09/594,703 patent/US6369224B1/en not_active Expired - Lifetime
- 2000-07-20 HK HK00104490A patent/HK1025322A1/xx not_active IP Right Cessation
-
2001
- 2001-03-28 HK HK01102261A patent/HK1031382A1/xx not_active IP Right Cessation
-
2002
- 2002-03-08 US US10/093,939 patent/US6703502B2/en not_active Expired - Fee Related
- 2002-10-16 HK HK02107504.2A patent/HK1046274B/zh not_active IP Right Cessation
-
2003
- 2003-03-24 US US10/396,215 patent/US6706878B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 US US10/801,085 patent/US7507744B2/en not_active Expired - Fee Related
-
2005
- 2005-03-16 IS IS7747A patent/IS2434B/is unknown
-
2008
- 2008-03-13 US US12/047,425 patent/US20080153864A1/en not_active Abandoned
- 2008-08-22 AR ARP080103670A patent/AR068013A2/es active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE04399B1 (et) | Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis | |
EE04463B1 (et) | 3-arüülpropaanhappe derivaadid ja nende analoogid, nende valmistamise meetod, neid sisaldavad ravimkoostised ja ühendid kasutamiseks ravis | |
EE9700153A (et) | Heterotsükliga kondenseerunud püridiinid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid | |
EE05001B1 (et) | Heterotsüklilised ühendid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis | |
EE200000168A (et) | Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid | |
EE9700060A (et) | 2-arüül-asendatud püridiinid,nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid | |
EE200000707A (et) | Oksasolidinooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid | |
EE05134B1 (et) | Adamantaani derivaadid, meetod nende valmistamiseks, neid sisaldavad ravimkoostised ja nende kasutamine ravis | |
EE200100484A (et) | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid,ja nende valmistamise meetodid | |
EE9700020A (et) | Heteroaatomit sisaldavad tsülopentaanpüridüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid | |
ZA989790B (en) | Novel heterocyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | |
EE9800028A (et) | Iprotroopiumsoolad, neid sisaldavad ravimkompositsioonid ja nende kasutamine | |
EE200100446A (et) | Uued tritsüklilised ühendid ja nende kasutamine meditsiinis: nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid | |
EE04498B1 (et) | Erütromütsiini derivaadid, nende valmistamismeetod ja neid sisaldav farmatseutiline kompositsioon | |
EE200100037A (et) | Bensotsüklohepteenid, nende valmistamise meetod, neid sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks | |
EE9900115A (et) | Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod | |
EE04748B1 (et) | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks | |
EE04021B1 (et) | 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks | |
EE9700019A (et) | 2-okso- ja 2-tio1,2-dihüdrokinolinüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid | |
EE04151B1 (et) | Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena | |
EE9800426A (et) | Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid | |
EE03825B1 (et) | 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
IL112443A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical compositions containing them | |
FI950625A (fi) | Polysubstituoituja 3-asyyliamino-5-fenyyli-1,4-bentsodiatsepiini-2-onijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia | |
EE04346B1 (et) | Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change of owner name | ||
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20090710 |